Accession Number : ADP006560
Title : Vaccination Against Hepatitis B: The Italian Strategy,
Corporate Author : CAMERINO UNIV (ITALY)
Personal Author(s) : Zanetti, A.R. ; Grappasonni, J. ; Tanzi, E. ; Romano, L.
Report Date : APR 1992
Pagination or Media Count : 3
Abstract : Viral hepatitis type B is major worldwide public health problem. Infection with the hepatitis B virus (HBV) may progress to chronic liver disease including chronic active hepatitis, cirrhosis and hepatocellular carcinoma. Moreover it has been estimated that between 200 and 300 million individuals in the world are chronic carriers of HBV. The availability of safe and effective vaccines allows the establishment of immunization programs aimed at the elimination of hepatitis B and the reduction of morbidity and mortality due to its sequelae. Vaccines against hepatitis type B. Currently available vaccines include plasma-derived vaccines and yeast-derived vaccines. Plasma-derived vaccines, introduced in 1981, were the first available vaccines to provide active protection against HBV.
Descriptors : *CANCER, *HEPATITIS, *IMMUNIZATION, *PUBLIC HEALTH, *AEROSPACE MEDICINE, DISEASES, ELIMINATION, HEALTH, LIVER, LIVER DISEASES, MORBIDITY, PROTECTION, REDUCTION, VACCINES, YEASTS, MORTALITY RATE.
Subject Categories : Medicine and Medical Research
Distribution Statement : APPROVED FOR PUBLIC RELEASE